Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial

  title={Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial},
  author={Turo Nurmikko and Michael G. Serpell and Barbara Hoggart and P. J. Toomey and Bart Morlion and Derek R Haines},

Figures and Tables from this paper

Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis

No new safety concerns were identified with chronic Sativex treatment, and serious AEs were uncommon, and patients who remained in the study reported continued benefit.

Smoked cannabis for chronic neuropathic pain: a randomized controlled trial

A single inhalation of 25 mg of 9.4% tetrahydrocannabinol herbal cannabis three times daily for five days reduced the intensity of pain, improved sleep and was well tolerated, and no differences in mood or quality of life were found.

Evaluation of the analgesic efficacy and psychoactive effects of AZD1940, a novel peripherally acting cannabinoid agonist, in human capsaicin‐induced pain and hyperalgesia

The emergence of mild dose‐dependent CNS effects suggests that the dose range predicted from preclinical data had been attained, and no evidence of analgesic efficacy was found for a peripherally acting CB1/CB2 receptor agonist in the human capsaicin pain model.

Selective Cannabinoids for Chronic Neuropathic Pain: A Systematic Review and Meta-analysis

Well-designed, large, randomized studies are required to better evaluate specific dosage, duration of intervention, and the effect of this intervention on physical and psychologic function in patients with chronic NP.

Analgesic and antihyperalgesic effects of nabilone on experimental heat pain

Preliminary results suggest that nabilone appears effective at relieving hyperalgesic responses in women, and it is found that a single 1 mg dose of nabil one reduced temporal summation for women but not men.

Cannabinoids in the management of diffi cult to treat pain

This article reviews recent research on cannabinoid analgesia via the endocannabinoid system and non-receptor mechanisms, as well as randomized clinical trials employing canna- binoids in pain

Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis.

The data suggest that Sativex may be effective in improving MS-related neuropathic pain, maybe through its action on specific cortical pathways.

Role of Cannabinoids in the Treatment of Pain and (Painful) Spasticity

Patients with unsatisfactory response to other methods of pain therapy and who were characterized by failed stress adaptation particularly benefited from treatment with cannabinoids, but none of the attempts to overcome the disadvantage of the narrow therapeutic index have resulted in a major breakthrough.

Lack of effect of central nervous system‐active doses of nabilone on capsaicin‐induced pain and hyperalgesia

The aim of the present study was to investigate the effects of nabilone on capsaicin‐induced pain and hyperalgesia, as well as on biomarkers of cannabinoid central nervous system (CNS) effects. A



Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial

Dronabinol has a modest but clinically relevantanalgesic effect on central pain in patients with multiple sclerosis and on the SF-36 quality of life scale, the two items bodily pain and mental health indicated benefits from active treatment compared with placebo.

Efficacy of Oral Mexiletine for Neuropathic Pain With Allodynia: A Double-Blind, Placebo-Controlled, Crossover Study

At doses of up to 900 mg/d, mexiletine has minimal effects on pain and allodynia of neuropathic pain, however, side effects may preclude higher doses.

Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial.

In this preliminary study, CT-3 was effective in reducing chronic neuropathic pain compared with placebo and no major adverse effects were observed.

Cannabis in painful HIV-associated sensory neuropathy

Smoked cannabis was well tolerated and effectively relieved chronic neuropathic pain from HIV-associated sensory neuropathy and the findings are comparable to oral drugs used for chronic Neuropathic pain.

Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.

Gabapentin monotherapy appears to be efficacious for the treatment of pain and sleep interference associated with diabetic peripheral neuropathy and exhibits positive effects on mood and quality of life.

Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis

CBM was generally well tolerated, although more patients on CBM than placebo reported dizziness, dry mouth, and somnolence, and Cognitive side effects were limited to long-term memory storage.